<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00150072</url>
  </required_header>
  <id_info>
    <org_study_id>CSTI571BIT15</org_study_id>
    <nct_id>NCT00150072</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Imatinib in Chordoma</brief_title>
  <official_title>Phase II Study of Imatinib Mesylate in Chordoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Preliminary response data, observed by Casali (Cancer, 2004) with imatinib 800 mg/day in&#xD;
      patients affected by chordoma, need to be confirmed by a Phase II study, whose primary&#xD;
      endpoint will be the formal assessment of clinical and pathological response. Aim of the&#xD;
      study will be to explore treatment's activity, but also the potential impact of tumor&#xD;
      response, the feasibility and outcome of subsequent surgery and radiotherapy. In addition,&#xD;
      patterns of tumour response need to be investigated as well, given the peculiar patterns of&#xD;
      response shown with molecular-targeted therapy in solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Every 3 months for 2 years</time_frame>
    <description>objective response according to RECIST and clinical response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>from the first day of sudy treatment to the day of death for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>from the first day of sudy treatment to the day of death for any cause or documented progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>2 years</time_frame>
    <description>frequency of adverse events, abnormal lab values, bone pain, use of analgesic medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients undergoing complete surgery</measure>
    <time_frame>2 years</time_frame>
    <description>number of pts undergoing complete surgery vs the one of pts not amenable to complete surgery at enrolment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Chordoma</condition>
  <arm_group>
    <arm_group_label>imatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib</intervention_name>
    <arm_group_label>imatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological diagnosis of chordoma.&#xD;
&#xD;
          2. Biomolecular or immunohistochemical evidence of Imatinib mesylate target (PDGFRβ&#xD;
             activation and/or presence of PDGFB). Biomolecular assessment of PDGFRβ activation&#xD;
             should be made whenever possible. To this end, if frozen material is not available,&#xD;
             obtaining of, fresh material is encouraged, if it should be obtained with no major&#xD;
             distress for the patient, preferably through an incisional biopsy (to allow&#xD;
             immunoprecipitation) or, if this is not feasible, a Trucut biopsy (to allow Western&#xD;
             Blot assessment). However, if frozen or fresh material cannot be obtained, paraffined&#xD;
             material is also acceptable.&#xD;
&#xD;
             The biomolecular assessment will be centralized to the reference centers (to be&#xD;
             defined).&#xD;
&#xD;
          3. Measurable or evaluable disease&#xD;
&#xD;
          4. Surgical resection of local disease unfeasible radically, or unaccepted by the&#xD;
             patient, or amenable to become less demolitive, or easier, or likely more feasible,&#xD;
             after cytoreduction, and/or metastatic disease. Debulking surgery before enrolment is&#xD;
             allowed. In this case, enrolment should occur at least one month after surgery&#xD;
&#xD;
          5. Performance status 0, 1, 2 or 3 (ECOG) (see § 8.1).&#xD;
&#xD;
          6. Adequate end organ function, defined as the following: total bilirubin &lt;1.5 x ULN,&#xD;
             SGOT and SGPT &lt;2.5 x UNL (or &lt;5 x ULN if hepatic metastases are present), creatinine&#xD;
             &lt;1.5 x ULN.&#xD;
&#xD;
          7. Adequate bone marrow function, defined as the following: ANC &gt;1.5 x 10^9/L, platelets&#xD;
             &gt;100 x 10^9/L, Hb &gt;9 g/dL. Blood transfusions are allowed to reach the baseline&#xD;
             requested Hb level.&#xD;
&#xD;
          8. Female patients of child-bearing potential must have negative pregnancy test within 7&#xD;
             days before initiation of study drug dosing. Post menopausal women must be amenorrheic&#xD;
             for at least 12 months to be considered of non-childbearing potential. Male and female&#xD;
             patients of reproductive potential must agree to employ an effective method of birth&#xD;
             control throughout the study and for up to 3 months following discontinuation of study&#xD;
             drug.&#xD;
&#xD;
          9. Written, voluntary, informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with any other investigational or not investigational agents within&#xD;
             28 days of first day of study drug dosing.&#xD;
&#xD;
          2. Other primary malignancy with &lt;5 years clinically assessed disease-free interval,&#xD;
             except basal cell skin cancer, cervical carcinoma in situ, or other neoplasms judged&#xD;
             to entail a low risk of relapse.&#xD;
&#xD;
          3. Grade III/IV cardiac problems as defined by the New York Heart Association Criteria&#xD;
             (i.e., congestive heart failure, myocardial infarction within 6 months of study)&#xD;
&#xD;
          4. Severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal&#xD;
             disease, or active uncontrolled infection).&#xD;
&#xD;
          5. Known brain metastasis.&#xD;
&#xD;
          6. Known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).&#xD;
&#xD;
          7. Known diagnosis of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          8. Previous radiotherapy to &gt;=25 % of the bone marrow.&#xD;
&#xD;
          9. Major surgery within 2 weeks prior to study entry.&#xD;
&#xD;
         10. Expected non-compliance to medical regimens.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Candiolo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Koren-Michowitz M, le Coutre P, Duyster J, Scheid C, Panayiotidis P, Prejzner W, Rowe JM, Schwarz M, Goldschmidt N, Nagler A. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant. Cancer. 2010 Oct 1;116(19):4564-72. doi: 10.1002/cncr.25351. Erratum in: Cancer. 2011 Jan 1;117(1):230.</citation>
    <PMID>20572041</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chordoma</keyword>
  <keyword>imatinib</keyword>
  <keyword>PDGFR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chordoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

